Literature DB >> 22358926

Controllable genetic manipulation of apoptosis of cells in culture.

T Littlewood1, N McCarthy, M Whyte, S Pelengaris, C James, G Evan.   

Abstract

Apoptosis of mammalian cell is under the control of a wide range of intracellular and extracellular factors-amongst them proteases, protein kinases, cytokines and the protein products of oncogenes and tumour suppressor genes. The c-myc proto-oncogene encodes an essential component of the cell's proliferative machinery and its deregulated expression is implicated in many cancers. Under certain conditions, c-Myc also acts as a potent inducer of apoptosis. We have developed a 'switchable' chimaeric c-Myc protein whose activity is dependent on the synthetic ligand, 4-hydroxytamoxifen. In cells expressing this switchable c-Myc, proliferation and apoptosis in cultured fibroblasts can be regulated by addition of 4-hydroxytamoxifen. We have further demonstrated the utility of a switchable gene transcription system for the induction of proteins with pro-apoptotic effect. Myc-induced apoptosis is inhibited by the action of certain cytokines or by expresson of exogenous proteins with anti-apoptotic potential such as Bcl-2. We show that inhibition of p53 using dominant negative molecules inhibits apoptosis induced by DNA damage but has little effect on Myc-induced apoptosis. Finally, we have also been able to modulate a relatively late stage in apoptosis using inhibitors of cysteine proteases. Our data suggest a model in which the integrated activities of several proteins with diverse molecular functions may determine whether a particular cell undergoes apoptosis but that, once the actual catalytic machinery is engaged, the apoptotic process is irreversible.

Entities:  

Year:  1996        PMID: 22358926     DOI: 10.1007/BF00353935

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  43 in total

1.  Myc and Max associate in vivo.

Authors:  E M Blackwood; B Lüscher; R N Eisenman
Journal:  Genes Dev       Date:  1992-01       Impact factor: 11.361

Review 2.  myc family oncogenes in the development of normal and neoplastic cells.

Authors:  R A DePinho; N Schreiber-Agus; F W Alt
Journal:  Adv Cancer Res       Date:  1991       Impact factor: 6.242

3.  Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis.

Authors:  M Los; M Van de Craen; L C Penning; H Schenk; M Westendorp; P A Baeuerle; W Dröge; P H Krammer; W Fiers; K Schulze-Osthoff
Journal:  Nature       Date:  1995-05-04       Impact factor: 49.962

Review 4.  Patterns of cell death.

Authors:  N I Walker; B V Harmon; G C Gobé; J F Kerr
Journal:  Methods Achiev Exp Pathol       Date:  1988

5.  Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells.

Authors:  M Eilers; D Picard; K R Yamamoto; J M Bishop
Journal:  Nature       Date:  1989-07-06       Impact factor: 49.962

6.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.

Authors:  B Amati; S Dalton; M W Brooks; T D Littlewood; G I Evan; H Land
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

7.  Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2.

Authors:  A J Wagner; M B Small; N Hay
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

8.  Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1.

Authors:  S O Freytag
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

9.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.

Authors:  T D Littlewood; D C Hancock; P S Danielian; M G Parker; G I Evan
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

10.  The MYC protein activates transcription of the alpha-prothymosin gene.

Authors:  M Eilers; S Schirm; J M Bishop
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.